Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
3 April 2017
E-002453-17
Question for written answer
to the Commission
Rule 130
Jean-François Jalkh (ENF)

 Subject:  Recognition of Lyme disease
 Answer(s) 

I have, for some time, been receiving a stream of messages from people who have been directly or indirectly affected by the bacteria that causes Lyme disease. It appears that its status as a rare disease, agreed by consensus in 2006, prevents patients from receiving optimal care.

According to those contacting me, screening methods for the disease in some countries are organised in such a way that only a marginal number of positive tests emerge, of which the outcome is often uncertain in the medical world. They therefore ask that Lyme disease be recognised as a chronic disease, and that the veterinary test called PCR (Polymerase Chain Reaction), the only reliable test able to detect the disease by directly identifying the bacteria’s DNA, be approved.

The fact that it is not recognised as such forces citizens of certain countries to go abroad to receive treatment, which generates considerable costs.

Does the Commission intend to launch a large-scale enquiry into this evidently anonymous public health issue?

Original language of question: FR 
Last updated: 26 April 2017Legal notice